


WHAT IS CLAIMED IS:

## 1. A compound of the Formula A:



5 wherein:

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

10 n is 0, 1 or 2;

p is 0, 1, 2 or 3;

r is 0 or 1;

s is 0 or 1;

t is 2, 3, 4, 5 or 6;

15

u, v and x are independently selected from: CH and N;

w is selected from a bond, CH and N;

20 y and z are independently selected from: CH and N, provided that at least one of y and z is N;

R<sup>1</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 25 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,

- 6)  $(C=O)_a O_b C_3-C_8$  cycloalkyl,
- 7)  $CO_2H$ ,
- 8) halo,
- 9) CN,
- 5 10) OH,
- 11)  $O_b C_1-C_6$  perfluoroalkyl,
- 12)  $O_a(C=O)_b NR^7 R^8$ ,
- 13)  $NR^c(C=O)NR^7 R^8$ ,
- 14)  $S(O)_m R^a$ ,
- 10 15)  $S(O)_2 NR^7 R^8$ ,
- 16)  $NR^c S(O)_m R^a$ ,
- 17) oxo,
- 18) CHO,
- 19)  $NO_2$ ,
- 15 20)  $NR^c(C=O)O_b R^a$ ,
- 21)  $O(C=O)O_b C_1-C_{10}$  alkyl,
- 22)  $O(C=O)O_b C_3-C_8$  cycloalkyl,
- 23)  $O(C=O)O_b$  aryl, and
- 24)  $O(C=O)O_b$ -heterocycle,

20 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from  $R^Z$ ;

$R^2$  is independently selected from:

- 1)  $(C=O)_a O_b C_1-C_{10}$  alkyl,
- 25 2)  $(C=O)_a O_b$  aryl,
- 3)  $C_2-C_{10}$  alkenyl,
- 4)  $C_2-C_{10}$  alkynyl,
- 5)  $(C=O)_a O_b$  heterocyclyl,
- 6)  $(C=O)_a O_b C_3-C_8$  cycloalkyl,
- 30 7)  $CO_2H$ ,
- 8) halo,
- 9) CN,
- 10) OH,
- 11)  $O_b C_1-C_6$  perfluoroalkyl,

- 12)  $O_a(C=O)_bNR^7R^8$ ,
- 13)  $NR^c(C=O)NR^7R^8$ ,
- 14)  $S(O)_mR^a$ ,
- 15)  $S(O)_2NR^7R^8$ ,
- 5 16)  $NR^cS(O)_mR^a$ ,
- 17)  $CHO$ ,
- 18)  $NO_2$ ,
- 19)  $NR^c(C=O)ObR^a$ ,
- 20)  $O(C=O)ObC_1-C_{10}$  alkyl,
- 10 21)  $O(C=O)ObC_3-C_8$  cycloalkyl,
- 22)  $O(C=O)Obaryl$ , and
- 23)  $O(C=O)Ob$ -heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

15 R<sup>3</sup> and R<sup>4</sup> are independently selected from: H, C<sub>1</sub>-C<sub>6</sub>-alkyl and C<sub>1</sub>-C<sub>6</sub>-perfluoroalkyl, or

20 R<sup>3</sup> and R<sup>4</sup> are combined to form -(CH<sub>2</sub>)<sub>t</sub>- wherein one of the carbon atoms is optionally replaced by a moiety selected from O, S(O)<sub>m</sub>, -N(R<sup>b</sup>)C(O)-, and -N(COR<sup>a</sup>)-;

R<sup>5</sup> and R<sup>6</sup> are independently selected from:

- 1) H,
- 25 2)  $(C=O)ObR^a$ ,
- 3) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 4) aryl,
- 5) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 6) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 30 7) heterocyclyl,
- 8) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 9) SO<sub>2</sub>R<sup>a</sup>, and
- 10)  $(C=O)NR^{b_2}$ ,

said alkyl, cycloalkyl, aryl, heterocyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

R<sup>5</sup> and R<sup>6</sup> can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with Q and also optionally substituted with one or more substituents selected from R<sup>Z</sup>;

10 R<sup>7</sup> and R<sup>8</sup> are independently selected from:

- 1) H,
- 2) (C=O)ObC<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) (C=O)ObC<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 4) (C=O)Obaryl,
- 15 5) (C=O)Obheterocyclyl,
- 6) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 7) aryl,
- 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 20 10) heterocyclyl,
- 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 12) SO<sub>2</sub>R<sup>a</sup>, and
- 13) (C=O)NR<sup>b</sup><sub>2</sub>,

said alkyl, cycloalkyl, aryl, heterocyl, alkenyl, and alkynyl is optionally substituted

25 with one or more substituents selected from R<sup>Z</sup>, or

R<sup>7</sup> and R<sup>8</sup> can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>Z</sup> is selected from:

- 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
- 35 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,

- 3)  $(C_0\text{-}C_6)\text{alkylene-S(O)}_m R^a$ ,
- 4) oxo,
- 5) OH,
- 6) halo,
- 5) CN,
- 8)  $(C=O)_r Os(C_2\text{-}C_{10})\text{alkenyl}$ ,
- 9)  $(C=O)_r Os(C_2\text{-}C_{10})\text{alkynyl}$ ,
- 10)  $(C=O)_r Os(C_3\text{-}C_6)\text{cycloalkyl}$ ,
- 11)  $(C=O)_r Os(C_0\text{-}C_6)\text{alkylene-aryl}$ ,
- 10)  $(C=O)_r Os(C_0\text{-}C_6)\text{alkylene-heterocyclyl}$ ,
- 13)  $(C=O)_r Os(C_0\text{-}C_6)\text{alkylene-N(R^b)}_2$ ,
- 14)  $C(O)R^a$ ,
- 15)  $(C_0\text{-}C_6)\text{alkylene-CO}_2R^a$ ,
- 16)  $C(O)H$ ,
- 15)  $(C_0\text{-}C_6)\text{alkylene-CO}_2H$ ,
- 18)  $C(O)N(R^b)_2$ ,
- 19)  $S(O)_m R^a$ ,
- 20)  $S(O)_2 N(R^b)_2$ ,
- 21)  $N R^c (C=O) O_b R^a$ ,
- 20)  $O(C=O) O_b C_1\text{-}C_{10} \text{ alkyl}$ ,
- 23)  $O(C=O) O_b C_3\text{-}C_8 \text{ cycloalkyl}$ ,
- 24)  $O(C=O) O_b \text{aryl}$ , and
- 25)  $O(C=O) O_b \text{-heterocycle}$ ,

25 said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from  $R^b$ , OH,  $(C_1\text{-}C_6)\text{alkoxy}$ , halogen,  $CO_2H$ ,  $CN$ ,  $O(C=O)C_1\text{-}C_6$  alkyl, oxo, and  $N(R^b)_2$ ;

30  $R^a$  is substituted or unsubstituted  $(C_1\text{-}C_6)\text{alkyl}$ , substituted or unsubstituted  $(C_2\text{-}C_6)\text{alkenyl}$ , substituted or unsubstituted  $(C_2\text{-}C_6)\text{alkynyl}$ , substituted or unsubstituted  $(C_3\text{-}C_6)\text{cycloalkyl}$ , substituted or unsubstituted aryl,  $(C_1\text{-}C_6)\text{perfluoroalkyl}$ , 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R<sup>b</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocycll, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;


5 R<sup>c</sup> is selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) aryl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 10 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 6) heterocycll,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted  
15 with one or more substituents selected from R<sup>z</sup>, or

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. A compound of the Formula B:



20

wherein:

a is 0 or 1;

b is 0 or 1;

25 m is 0, 1 or 2;

n is 0, 1 or 2;

p is 0, 1 or 2;

q is 0, 1, 2, 3 or 4;

r is 0 or 1;

s is 0 or 1;

5 t is 2, 3, 4, 5 or 6;

u, v and x are independently selected from: CH and N;

w is selected from a bond, CH and N;

10

Q is selected from: -NR<sup>7</sup>R<sup>8</sup>, aryl and heterocyclyl, said aryl and heterocyclyl optionally substituted with one to three substituents selected from R<sup>2</sup>;

R<sup>1</sup> is independently selected from:

- 15 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 20 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 7) CO<sub>2</sub>H,
- 8) halo,
- 9) CN,
- 10) OH,
- 25 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,
- 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,
- 14) S(O)<sub>m</sub>R<sup>a</sup>,
- 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,
- 30 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,
- 17) oxo,
- 18) CHO,
- 19) NO<sub>2</sub>,
- 20) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 35 21) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,

- 22) O(C=O)ObC<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 23) O(C=O)Obaryl, and
- 24) O(C=O)Ob-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted

5 with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>ObC<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>Obaryl,
- 10 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>Ob heterocyclyl,
- 6) (C=O)<sub>a</sub>ObC<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 7) CO<sub>2</sub>H,
- 15 8) halo,
- 9) CN,
- 10) OH,
- 11) ObC<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,
- 20 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,
- 14) S(O)<sub>m</sub>R<sup>a</sup>,
- 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,
- 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,
- 17) CHO,
- 25 18) NO<sub>2</sub>,
- 19) NR<sup>c</sup>(C=O)ObR<sup>a</sup>,
- 20) O(C=O)ObC<sub>1</sub>-C<sub>10</sub> alkyl,
- 21) O(C=O)ObC<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 22) O(C=O)Obaryl, and
- 30 23) O(C=O)Ob-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

R<sup>3</sup> and R<sup>4</sup> are independently selected from: H, C<sub>1</sub>-C<sub>6</sub>-alkyl and C<sub>1</sub>-C<sub>6</sub>-perfluoroalkyl, or

R<sup>3</sup> and R<sup>4</sup> are combined to form -(CH<sub>2</sub>)<sub>t</sub>- wherein one of the carbon atoms is optionally replaced by a moiety selected from O, S(O)<sub>m</sub>, -N(R<sup>b</sup>)C(O)-, and -N(COR<sup>a</sup>)-;

5

R<sup>7</sup> and R<sup>8</sup> are independently selected from:

- 1) H,
- 2) (C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) (C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 4) (C=O)O<sub>b</sub>aryl,
- 5) (C=O)O<sub>b</sub>heterocyclyl,
- 6) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 7) aryl,
- 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 10) heterocyclyl,
- 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 12) SO<sub>2</sub>R<sup>a</sup>, and
- 13) (C=O)NR<sup>b</sup><sub>2</sub>,

10 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

15 R<sup>7</sup> and R<sup>8</sup> can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>;

20 R<sup>Z</sup> is selected from:

- 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
- 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,
- 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
- 4) oxo,
- 5) OH,
- 35 6) halo,

- 7) CN,
- 8)  $(C=O)_rOs(C_2-C_{10})$ alkenyl,
- 9)  $(C=O)_rOs(C_2-C_{10})$ alkynyl,
- 10)  $(C=O)_rOs(C_3-C_6)$ cycloalkyl,
- 5 11)  $(C=O)_rOs(C_0-C_6)$ alkylene-aryl,
- 12)  $(C=O)_rOs(C_0-C_6)$ alkylene-heterocyclyl,
- 13)  $(C=O)_rOs(C_0-C_6)$ alkylene-N(R<sup>b</sup>)<sub>2</sub>,
- 14) C(O)R<sup>a</sup>,
- 15)  $(C_0-C_6)$ alkylene-CO<sub>2</sub>R<sup>a</sup>,
- 10 16) C(O)H,
- 17)  $(C_0-C_6)$ alkylene-CO<sub>2</sub>H,
- 18) C(O)N(R<sup>b</sup>)<sub>2</sub>,
- 19) S(O)<sub>m</sub>R<sup>a</sup>,
- 20) S(O)<sub>2</sub>N(R<sup>b</sup>)<sub>2</sub>,
- 15 21) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 24) O(C=O)O<sub>b</sub>aryl, and
- 25) O(C=O)O<sub>b</sub>-heterocycle,

20 said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N(R<sup>b</sup>)<sub>2</sub>;

25 R<sup>a</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, substituted or unsubstituted aryl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R<sup>b</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;

30

R<sup>c</sup> is selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) aryl,


- 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 6) heterocyclyl,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 5) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

or a pharmaceutically acceptable salt or a stereoisomer thereof.

10

3. The compound according to Claim 1 which is:



wherein:

15 a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

n is 0, 1 or 2;

p is 0, 1 or 2;

20 r is 0 or 1;

s is 0 or 1;

u, v and x are independently selected from: CH and N;

w is selected from a bond, CH and N;

25

Q is selected from: -NR<sup>7</sup>R<sup>8</sup> and heterocyclyl, said heterocyclyl optionally substituted with one to three substituents selected from R<sup>Z</sup>;

R<sup>1</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 7) CO<sub>2</sub>H,
- 8) halo,
- 9) CN,
- 10) OH,
- 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,
- 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,
- 14) S(O)<sub>m</sub>R<sup>a</sup>,
- 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,
- 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,
- 17) oxo,
- 18) CHO,
- 19) NO<sub>2</sub>,
- 20) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 21) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 22) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 23) O(C=O)O<sub>b</sub>aryl, and
- 24) O(C=O)O<sub>b</sub>-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,

6)  $(C=O)_a O_b C_3-C_8$  cycloalkyl,  
7)  $CO_2H$ ,  
8) halo,  
9) CN,  
5 10) OH,  
11)  $O_b C_1-C_6$  perfluoroalkyl,  
12)  $O_a(C=O)_b NR^7R^8$ ,  
13)  $NR^c(C=O)NR^7R^8$ ,  
14)  $S(O)_m R^a$ ,  
10 15)  $S(O)_2 NR^7R^8$ ,  
16)  $NR^c S(O)_m R^a$ ,  
17) CHO,  
18)  $NO_2$ ,  
19)  $NR^c(C=O)O_b R^a$ ,  
15 20)  $O(C=O)O_b C_1-C_{10}$  alkyl,  
21)  $O(C=O)O_b C_3-C_8$  cycloalkyl,  
22)  $O(C=O)O_b$  aryl, and  
23)  $O(C=O)O_b$ -heterocycle,

20 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

R<sup>7</sup> and R<sup>8</sup> are independently selected from:

1) H,  
2)  $(C=O)O_b C_1-C_{10}$  alkyl,  
25 3)  $(C=O)O_b C_3-C_8$  cycloalkyl,  
4)  $(C=O)O_b$  aryl,  
5)  $(C=O)O_b$  heterocyclyl,  
6)  $C_1-C_{10}$  alkyl,  
7) aryl,  
30 8)  $C_2-C_{10}$  alkenyl,  
9)  $C_2-C_{10}$  alkynyl,  
10) heterocyclyl,  
11)  $C_3-C_8$  cycloalkyl,  
12)  $SO_2 R^a$ , and

13)  $(C=O)NR^b_2$ ,

said alkyl, cycloalkyl, aryl, heterocyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $R^Z$ , or

5       $R^7$  and  $R^8$  can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from  $R^Z$ ;

10

$R^Z$  is selected from:

- 1)  $(C=O)_rO_s(C_1-C_{10})$ alkyl,
- 2)  $O_r(C_1-C_3)$ perfluoroalkyl,
- 3)  $(C_0-C_6)$ alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
- 15     4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 8)  $(C=O)_rO_s(C_2-C_{10})$ alkenyl,
- 20     9)  $(C=O)_rO_s(C_2-C_{10})$ alkynyl,
- 10)  $(C=O)_rO_s(C_3-C_6)$ cycloalkyl,
- 11)  $(C=O)_rO_s(C_0-C_6)$ alkylene-aryl,
- 12)  $(C=O)_rO_s(C_0-C_6)$ alkylene-heterocycl,
- 13)  $(C=O)_rO_s(C_0-C_6)$ alkylene-N(R<sup>b</sup>)<sub>2</sub>,
- 25     14) C(O)R<sup>a</sup>,
- 15)  $(C_0-C_6)$ alkylene-CO<sub>2</sub>R<sup>a</sup>,
- 16) C(O)H,
- 17)  $(C_0-C_6)$ alkylene-CO<sub>2</sub>H,
- 18) C(O)N(R<sup>b</sup>)<sub>2</sub>,
- 30     19) S(O)<sub>m</sub>R<sup>a</sup>, and
- 20) S(O)<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>
- 21) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,

- 24) O(C=O)Obaryl, and
- 25) O(C=O)Ob-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H,

5 CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N(R<sup>b</sup>)<sub>2</sub>;

R<sup>a</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, substituted or unsubstituted aryl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

10 R<sup>b</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;


R<sup>c</sup> is selected from:

- 15 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) aryl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 20 6) heterocyclyl,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

25 or a pharmaceutically acceptable salt or a stereoisomer thereof.

4. The compound according to Claim 2 which is:



wherein:

5

- a is 0 or 1;
- b is 0 or 1;
- m is 0, 1 or 2;
- n is 0, 1 or 2;
- 10 p is 0, 1 or 2;
- r is 0 or 1;
- s is 0 or 1;

u, v and x are independently selected from: CH and N;

15

w is selected from a bond, CH and N;

Q is selected from: -NR<sup>7</sup>R<sup>8</sup>, phenyl, benzimidazolyl, benzimidazolonyl, quinolinyl and isoquinolinyl, said benzimidazolyl, benzimidazolonyl, quinolinyl and

20 isoquinolinyl optionally substituted with R<sup>z</sup>;

R<sup>1</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 25 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,

- 7) CO<sub>2</sub>H,
- 8) halo,
- 9) CN,
- 10) OH,
- 5 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,
- 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,
- 14) S(O)<sub>m</sub>R<sup>a</sup>,
- 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,
- 10 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,
- 17) oxo,
- 18) CHO,
- 19) NO<sub>2</sub>,
- 20) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 15 21) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 22) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 23) O(C=O)O<sub>b</sub>aryl, and
- 24) O(C=O)O<sub>b</sub>-heterocycle,

20 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 25 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 7) CO<sub>2</sub>H,
- 30 8) halo,
- 9) CN,
- 10) OH,
- 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,

- 13)  $\text{NR}^c(\text{C}=\text{O})\text{NR}^7\text{R}^8,$
- 14)  $\text{S}(\text{O})_m\text{R}^a,$
- 15)  $\text{S}(\text{O})_2\text{NR}^7\text{R}^8,$
- 16)  $\text{NR}^c\text{S}(\text{O})_m\text{R}^a,$
- 5      17)  $\text{CHO},$
- 18)  $\text{NO}_2,$
- 19)  $\text{NR}^c(\text{C}=\text{O})\text{ObR}^a,$
- 20)  $\text{O}(\text{C}=\text{O})\text{ObC}_1\text{-C}_{10}$  alkyl,
- 21)  $\text{O}(\text{C}=\text{O})\text{ObC}_3\text{-C}_8$  cycloalkyl,
- 10     22)  $\text{O}(\text{C}=\text{O})\text{Obaryl,}$  and
- 23)  $\text{O}(\text{C}=\text{O})\text{Ob-heterocycle,}$

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from  $\text{R}^z;$

15     $\text{R}^7$  and  $\text{R}^8$  are independently selected from:

- 1)  $\text{H},$
- 2)  $(\text{C}=\text{O})\text{ObC}_1\text{-C}_{10}$  alkyl,
- 3)  $(\text{C}=\text{O})\text{ObC}_3\text{-C}_8$  cycloalkyl,
- 4)  $(\text{C}=\text{O})\text{Obaryl,}$
- 20    5)  $(\text{C}=\text{O})\text{Obheterocyclyl,}$
- 6)  $\text{C}_1\text{-C}_{10}$  alkyl,
- 7) aryl,
- 8)  $\text{C}_2\text{-C}_{10}$  alkenyl,
- 9)  $\text{C}_2\text{-C}_{10}$  alkynyl,
- 25    10) heterocyclyl,
- 11)  $\text{C}_3\text{-C}_8$  cycloalkyl,
- 12)  $\text{SO}_2\text{R}^a,$  and
- 13)  $(\text{C}=\text{O})\text{NR}^b_2,$

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $\text{R}^z,$  or

$\text{R}^7$  and  $\text{R}^8$  can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected

from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>Z</sup> is selected from:

- 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
- 5 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,
- 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
- 4) oxo,
- 5) OH,
- 6) halo,
- 10 7) CN,
- 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl,
- 9) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl,
- 10) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
- 11) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl,
- 15 12) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl,
- 13) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>,
- 14) C(O)R<sup>a</sup>,
- 15) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>R<sup>a</sup>,
- 16) C(O)H,
- 20 17) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H,
- 18) C(O)N(R<sup>b</sup>)<sub>2</sub>,
- 19) S(O)<sub>m</sub>R<sup>a</sup>,
- 20) S(O)<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>
- 21) NR<sup>c</sup>(C=O)ObR<sup>a</sup>,
- 25 22) O(C=O)ObC<sub>1</sub>-C<sub>10</sub> alkyl,
- 23) O(C=O)ObC<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 24) O(C=O)Obaryl, and
- 25) O(C=O)Ob-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted

30 with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N(R<sup>b</sup>)<sub>2</sub>;

R<sup>a</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, aryl, or heterocyclyl; and

R<sup>b</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;


R<sup>c</sup> is selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) aryl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 6) heterocyclyl,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>z</sup>, or

15 or a pharmaceutically acceptable salt or a stereoisomer thereof.


5. The compound according to Claim 4 of the Formula D:



wherein

- 20 a is 0 or 1;
- b is 0 or 1;
- m is 0, 1 or 2;
- n is 0, 1 or 2;
- p is 0, 1 or 2;
- 25 r is 0 or 1;
- s is 0 or 1;
- u, v and x are independently selected from: CH and N;

w is selected from a bond, CH and N;



Q is selected from: -NR<sup>7</sup>R<sup>8</sup>,

R<sup>1</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 5 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 10 7) CO<sub>2</sub>H,
- 8) halo,
- 9) CN,
- 10) OH,
- 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 15 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,
- 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,
- 14) S(O)<sub>m</sub>R<sup>a</sup>,
- 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,
- 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,
- 20 17) oxo,
- 18) CHO,
- 19) NO<sub>2</sub>,
- 20) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 21) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 25 22) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 23) O(C=O)O<sub>b</sub>aryl, and
- 24) O(C=O)O<sub>b</sub>-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from:

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) aryl,
- 3) heterocyclyl,
- 5) 4) CO<sub>2</sub>H,
- 5) halo,
- 6) CN,
- 7) OH,
- 8) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,

10 said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

R<sup>7</sup> and R<sup>8</sup> are independently selected from:

- 1) H,
- 2) (C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) (C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 4) (C=O)Obaryl,
- 5) (C=O)Obheterocyclyl,
- 6) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 20 7) aryl,
- 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 10) heterocyclyl,
- 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 25 12) SO<sub>2</sub>R<sup>a</sup>, and
- 13) (C=O)NR<sup>b</sup><sub>2</sub>,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

30 R<sup>7</sup> and R<sup>8</sup> can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>Z</sup> is selected from:

- 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
- 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,
- 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
- 5      4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl,
- 10     9) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl,
- 10     10) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
- 11) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl,
- 12) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl,
- 13) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>,
- 15     14) C(O)R<sup>a</sup>,
- 15) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>R<sup>a</sup>,
- 16) C(O)H,
- 17) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H,
- 18) C(O)N(R<sup>b</sup>)<sub>2</sub>,
- 20     19) S(O)<sub>m</sub>R<sup>a</sup>,
- 20) S(O)<sub>2</sub>N(R<sup>b</sup>)<sub>2</sub>
- 21) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 25     24) O(C=O)O<sub>b</sub>aryl, and
- 25) O(C=O)O<sub>b</sub>-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N(R<sup>b</sup>)<sub>2</sub>;

30

R<sup>a</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, aryl, or heterocyclyl; and

R<sup>b</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;

R<sup>c</sup> is selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 5 3) aryl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 6) heterocyclyl,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 10 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

or a pharmaceutically acceptable salt or a stereoisomer thereof.


15

6. The TFA salt of a compound according to Claim 1 which is selected from:


- 1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 20 N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]metanamine;
- 25 1-{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 30 N-{(3R)-1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]pyrrolidin-3-yl}-1,3-thiazole-5-carboxamide;
- 35 tert-butyl 1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]azetidin-3-ylcarbamate;
- 9-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-9H-purin-6-amine;

35

6-(4-{[4-(3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]methyl}phenyl)-7-phenyl-1H-imidazo[4,5-g]quinoxaline;




;




;





5




;



;



; and



or a stereoisomer thereof.

7. A compound which is selected from:

1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]metanamine;


1-{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;


N-{(3R)-1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]pyrrolidin-3-yl}-1,3-thiazole-5-carboxamide;

tert-butyl 1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]azetidin-3-ylcarbamate;


9-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-9H-purin-6-amine;

6-(4-{{4-(3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl}methyl}phenyl)-7-phenyl-1H-imidazo[4,5-g]quinoxaline;







;




;




;



;



;



or a pharmaceutically acceptable salt or a stereoisomer thereof.

5

8. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

10

9. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 7.

15

10. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.

11. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 7.

5 12. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

10 13. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 7.

15 14. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

15 15. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.

20 16. The composition of Claim 8 further comprising a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) a PPAR- $\gamma$  agonists,
- 12) a PPAR- $\delta$  agonists,
- 13) an inhibitor of cell proliferation and survival signaling, and
- 14) an agent that interferes with a cell cycle checkpoint.

17. The composition of Claim 16, wherein the second compound is  
an angiogenesis inhibitor selected from the group consisting of a tyrosine kinase  
inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-  
derived growth factor, an inhibitor of platelet derived growth factor, an MMP  
inhibitor, an integrin blocker, interferon-•, interleukin-12, pentosan polysulfate, a  
cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-  
O-(chloroacetyl-carbonyl)-fumagillo, thalidomide, angiostatin and troponin-1.

10 18. The composition of Claim 16, wherein the second compound is  
an estrogen receptor modulator selected from tamoxifen and raloxifene.

15 19. A method of treating cancer which comprises administering a  
therapeutically effective amount of a compound of Claim 1 in combination with  
radiation therapy.

20 20. A method of treating or preventing cancer which comprises  
administering a therapeutically effective amount of a compound of Claim 1 in  
combination with a compound selected from:

- 20 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 25 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 30 11) a PPAR-γ agonists,
- 12) a PPAR-δ agonists,
- 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 35 16) an agent useful in the treatment of neutropenia,

- 17) an immunologic-enhancing drug,
- 18) an inhibitor of cell proliferation and survival signaling, and
- 19) an agent that interferes with a cell cycle checkpoint.

5            21. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy and a compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 10          3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 15          8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) a PPAR- $\gamma$  agonists,
- 12) a PPAR- $\delta$  agonists,
- 20          13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 16) an agent useful in the treatment of neutropenia,
- 17) an immunologic-enhancing drug,
- 25          18) an inhibitor of cell proliferation and survival signaling, and
- 19) an agent that interferes with a cell cycle checkpoint.

30          22. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.